168 related articles for article (PubMed ID: 37733980)
1. Pretest Video Education Versus Genetic Counseling for Patients With Prostate Cancer: ProGen, A Multisite Randomized Controlled Trial.
Rana HQ; Stopfer JE; Weitz M; Kipnis L; Koeller DR; Culver S; Mercado J; Gelman RS; Underhill-Blazey M; McGregor BA; Sweeney CJ; Petrucelli N; Kokenakes C; Pirzadeh-Miller S; Reys B; Frazier A; Knechtl A; Fateh S; Vatnick DR; Silver R; Kilbridge KE; Pomerantz MM; Wei XX; Choudhury AD; Sonpavde GP; Kozyreva O; Lathan C; Horton C; Dolinsky JS; Heath EI; Ross TS; Courtney KD; Garber JE; Taplin ME
JCO Oncol Pract; 2023 Nov; 19(11):1069-1079. PubMed ID: 37733980
[TBL] [Abstract][Full Text] [Related]
2. Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs.
Russo J; McDougall C; Bowler N; Shimada A; Gross L; Hyatt C; Kelly WK; Calvaresi A; Handley NR; Hirsch IH; Izes JK; Lallas CD; Mann M; Mark JR; Mille PJ; Preate D; Trabulsi EJ; Tsang M; Chandrasekar T; Weiner PR; Gomella LG; Giri VN
JCO Precis Oncol; 2021; 5():. PubMed ID: 34589662
[TBL] [Abstract][Full Text] [Related]
3. TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing.
Loeb S; Keith SW; Cheng HH; Leader AE; Gross L; Sanchez Nolasco T; Byrne N; Hartman R; Brown LH; Pieczonka CM; Gomella LG; Kelly WK; Lallas CD; Handley N; Mille PJ; Mark JR; Brown GA; Chopra S; McClellan A; Wise DR; Hollifield L; Giri VN
JCO Precis Oncol; 2024 Mar; 8():e2300552. PubMed ID: 38452310
[TBL] [Abstract][Full Text] [Related]
4. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
Giri VN; Hegarty SE; Hyatt C; O'Leary E; Garcia J; Knudsen KE; Kelly WK; Gomella LG
Prostate; 2019 Mar; 79(4):333-339. PubMed ID: 30450585
[TBL] [Abstract][Full Text] [Related]
5. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.
Manchanda R; Loggenberg K; Sanderson S; Burnell M; Wardle J; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; McGuire A; Beller U; Menon U; Jacobs I
J Natl Cancer Inst; 2015 Jan; 107(1):379. PubMed ID: 25435541
[TBL] [Abstract][Full Text] [Related]
6. Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling.
Giri VN; Obeid E; Hegarty SE; Gross L; Bealin L; Hyatt C; Fang CY; Leader A
Prostate; 2018 Sep; 78(12):879-888. PubMed ID: 29655297
[TBL] [Abstract][Full Text] [Related]
7. Expanding access to BRCA1/2 genetic counseling with telephone delivery: a cluster randomized trial.
Kinney AY; Butler KM; Schwartz MD; Mandelblatt JS; Boucher KM; Pappas LM; Gammon A; Kohlmann W; Edwards SL; Stroup AM; Buys SS; Flores KG; Campo RA
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25376862
[TBL] [Abstract][Full Text] [Related]
8. High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study.
Nilsson MP; Nilsson ED; Borg Å; Brandberg Y; Silfverberg B; Loman N
Breast Cancer Res Treat; 2019 Jan; 173(2):313-318. PubMed ID: 30311024
[TBL] [Abstract][Full Text] [Related]
9. Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial.
Swisher EM; Rayes N; Bowen D; Peterson CB; Norquist BM; Coffin T; Gavin K; Polinsky D; Crase J; Bakkum-Gamez JN; Blank SV; Munsell MF; Nebgen D; Fleming GF; Olopade OI; Law S; Zhou A; Levine DA; D'Andrea A; Lu KH
JAMA Oncol; 2023 Nov; 9(11):1547-1555. PubMed ID: 37707822
[TBL] [Abstract][Full Text] [Related]
10. What men want: Qualitative analysis of what men with prostate cancer (PCa) want to learn regarding genetic referral, counseling, and testing.
Greenberg S; Slager S; Neil BO; Cooney K; Maughan B; Stopa N; Venne V; Zickmund S; Colonna S
Prostate; 2020 Apr; 80(5):441-450. PubMed ID: 32027768
[TBL] [Abstract][Full Text] [Related]
11. Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer.
Schwartz MD; Valdimarsdottir HB; Peshkin BN; Mandelblatt J; Nusbaum R; Huang AT; Chang Y; Graves K; Isaacs C; Wood M; McKinnon W; Garber J; McCormick S; Kinney AY; Luta G; Kelleher S; Leventhal KG; Vegella P; Tong A; King L
J Clin Oncol; 2014 Mar; 32(7):618-26. PubMed ID: 24449235
[TBL] [Abstract][Full Text] [Related]
12. Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients.
Breen KE; Symecko H; Spielman K; Gebert R; Shah IH; Pundock S; Batson M; Narayan VK; Stadler ZK; Autio KA; Abida W; Danila DC; Scher HI; Morris MJ; Hamilton JG; Robson ME; Domchek SM; Carlo MI
J Urol; 2023 May; 209(5):918-927. PubMed ID: 36974724
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of phone versus in-person BRCA1/2 predisposition genetic test result disclosure counseling.
Jenkins J; Calzone KA; Dimond E; Liewehr DJ; Steinberg SM; Jourkiv O; Klein P; Soballe PW; Prindiville SA; Kirsch IR
Genet Med; 2007 Aug; 9(8):487-95. PubMed ID: 17700386
[TBL] [Abstract][Full Text] [Related]
14. BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention.
McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
Am J Med Genet A; 2004 Oct; 130A(3):221-7. PubMed ID: 15378542
[TBL] [Abstract][Full Text] [Related]
15. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
Giri VN; Knudsen KE; Kelly WK; Cheng HH; Cooney KA; Cookson MS; Dahut W; Weissman S; Soule HR; Petrylak DP; Dicker AP; AlDubayan SH; Toland AE; Pritchard CC; Pettaway CA; Daly MB; Mohler JL; Parsons JK; Carroll PR; Pilarski R; Blanco A; Woodson A; Rahm A; Taplin ME; Polascik TJ; Helfand BT; Hyatt C; Morgans AK; Feng F; Mullane M; Powers J; Concepcion R; Lin DW; Wender R; Mark JR; Costello A; Burnett AL; Sartor O; Isaacs WB; Xu J; Weitzel J; Andriole GL; Beltran H; Briganti A; Byrne L; Calvaresi A; Chandrasekar T; Chen DYT; Den RB; Dobi A; Crawford ED; Eastham J; Eggener S; Freedman ML; Garnick M; Gomella PT; Handley N; Hurwitz MD; Izes J; Karnes RJ; Lallas C; Languino L; Loeb S; Lopez AM; Loughlin KR; Lu-Yao G; Malkowicz SB; Mann M; Mille P; Miner MM; Morgan T; Moreno J; Mucci L; Myers RE; Nielsen SM; O'Neil B; Pinover W; Pinto P; Poage W; Raj GV; Rebbeck TR; Ryan C; Sandler H; Schiewer M; Scott EMD; Szymaniak B; Tester W; Trabulsi EJ; Vapiwala N; Yu EY; Zeigler-Johnson C; Gomella LG
J Clin Oncol; 2020 Aug; 38(24):2798-2811. PubMed ID: 32516092
[TBL] [Abstract][Full Text] [Related]
16. A systematic review and meta-analysis of telephone vs in-person genetic counseling in BRCA1/BRCA2 genetic testing.
Bracke X; Roberts J; McVeigh TP
J Genet Couns; 2021 Apr; 30(2):563-573. PubMed ID: 33131182
[TBL] [Abstract][Full Text] [Related]
17. BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.
Nilsson MP; Törngren T; Henriksson K; Kristoffersson U; Kvist A; Silfverberg B; Borg Å; Loman N
Breast Cancer Res Treat; 2018 Feb; 168(1):117-126. PubMed ID: 29164420
[TBL] [Abstract][Full Text] [Related]
18. Commentary on: "Inherited DNA-repair gene mutations in men with metastatic prostate cancer." Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443-53.
Lee BH
Urol Oncol; 2017 Sep; 35(9):575-576. PubMed ID: 28789927
[TBL] [Abstract][Full Text] [Related]
19. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
Na R; Zheng SL; Han M; Yu H; Jiang D; Shah S; Ewing CM; Zhang L; Novakovic K; Petkewicz J; Gulukota K; Helseth DL; Quinn M; Humphries E; Wiley KE; Isaacs SD; Wu Y; Liu X; Zhang N; Wang CH; Khandekar J; Hulick PJ; Shevrin DH; Cooney KA; Shen Z; Partin AW; Carter HB; Carducci MA; Eisenberger MA; Denmeade SR; McGuire M; Walsh PC; Helfand BT; Brendler CB; Ding Q; Xu J; Isaacs WB
Eur Urol; 2017 May; 71(5):740-747. PubMed ID: 27989354
[TBL] [Abstract][Full Text] [Related]
20. Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing.
Loeb S; Cheng HH; Leader A; Gross L; Nolasco TS; Byrne N; Wise DR; Hollifield L; Brown LH; Slater E; Pieczonka C; Gomella LG; Kelly WK; Trabulsi EJ; Handley N; Lallas CD; Chandrasekar T; Mille P; Mann M; Mark JR; Brown G; Chopra S; Wasserman J; Phillips J; Somers P; Giri VN
Contemp Clin Trials; 2022 Aug; 119():106821. PubMed ID: 35710085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
